A superiority designed study of Uygur medicine Luo-Ou-Ke Zu-Pa and Chinese medicine Xiao-Qing-Long-Tang Decoction in the treatment of cold asthma
- Conditions
- asthma
- Registration Number
- ITMCTR2000003561
- Lead Sponsor
- Huashan Hospital Affiliated to Fudan University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1. Aged 18-75 years old at the time of enrollment;
2. Patients with bronchial asthma diagnosed by modern medicine, regular inhaled hormone therapy or other conventional treatment 3 months later, patients with bronchial asthma ACT score <20 points;
3. Patients with abnormal mucus type identified by Uighur medicine;
4. Patients without upper and lower respiratory tract infections and not taking oral and intravenous glucocorticoid therapy within 2 weeks;
5. Subjects voluntarily participated in the study and signed Informed consent.
1. Patients in acute attack stage, who need oral and intravenous glucocorticoid therapy;
2. Patients with abnormal blood type, abnormal savda type, and abnormal biliary type identified by Uygur medicine;
3. Combined Patients with COPD, pulmonary fibrosis, and a history of lung resection;
4. Pregnant or planning to become pregnant or breastfeeding women;
5. Patients with malignant tumors and hematological diseases;
6. Those who have participated in clinical trials of other drugs within 3 months;
7. Those with severe impairment of heart, liver, and kidney functions (heart function grades 3 to 4, ALT and/or AST exceeding 1.5 times the upper limit of normal, and Cr exceeding the upper limit of normal);
8. Those deemed unsuitable for inclusion by the investigator Other situations.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ACT;Peak expiratory flow rate (PEF) value and average daily diurnal variation rate;Exhaled nitric oxide (FeNO);
- Secondary Outcome Measures
Name Time Method